Quantcast
Home > Quotes > RARE
RARE

Ultragenyx Pharmaceutical Inc. Common Stock (RARE) Quote & Summary Data

$46.01
*  
1.30
2.75%
Get RARE Alerts
*Delayed - data as of Dec. 14, 2018  -  Find a broker to begin trading RARE now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
80
Today's High / Low
$ 47.48 / $ 45.01
Share Volume
554,556
50 Day Avg. Daily Volume
570,202
Previous Close
$ 47.31
52 Week High / Low
$ 90.98 / $ 41.67
Market Cap
2,327,168,270
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -4.07
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
2.14

Intraday Chart

Shares Traded

Share Volume:
554,556
50 Day Avg. Daily Volume:
570,202

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -4.07

Trading Range

The current last sale of $46.01 is 10.42% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 47.48 $ 90.98
 Low: $ 45.01 $ 41.67

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. We target diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no currently approved therapies. Since our inception in 2010, we have in-licensed potential treatments for multiple rare genetic disorders. Our strategy, which is predicated upon time- and cost-efficient drug development, allows us to pursue multiple programs in parallel with the goal of delivering safe and effective therapies to patients with the utmost urgency. Our approved product and current product candidate pipeline have been either in-licensed from academic institutions or derived from partnerships with other pharmaceutical companies.  ... More ...  


Risk Grade

Where does RARE fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 46.56
Open Date:
Dec. 14, 2018
Close Price:
$ 46.01
Close Date:
Dec. 14, 2018

Consensus Recommendation

Analyst Info